RT Book, Section
A1 Yanavitski, Marat
A1 Kapadia, Samir
A2 Baliga, R. R.
A2 Lilly, Scott M.
A2 Abraham, William T.
SR Print(0)
ID 1160207196
T1 Interventional Treatment of Mitral Regurgitation
T2 Color Atlas and Synopsis of Interventional Cardiology
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071749350
LK accesscardiology.mhmedical.com/content.aspx?aid=1160207196
RD 2024/04/19
AB Chronic  mitral  regurgitation  (MR)  is  a  common  condition  that,  if  left  untreated,  results  in  progressive  heart  failure,  left  ventricular  (LV)  cavity  dilation  and  systolic  dysfunction,  left  atrial  enlargement,  atrial  fibrillation,  and  pulmonary  hypertension.  Although  medical  therapy  may  provide  some  symptomatic  relief  and  is  used  to  manage  underlying  ischemic  heart  disease  and  heart  failure  in  patients  with  MR,  it  has  not  been  shown  to  provide  benefit  in  prevention  of  development  of  heart  failure.1  The  current  mainstay  of  therapy,  surgical  correction  with  mitral  valve  repair  or  replacement,  is  unavailable  in  approximately  50%  of  patients  with  severe  MR  due  to  the  invasive  nature  of  open-heart  surgery  and  frequent  presence  of  comorbidities  in  this  group.2  Consequently,  percutaneous  technologies,  with  the  potential  benefit  of  decreased  morbidity,  improved  recovery  time,  and  shorter  hospital  stay,  provide  an  exciting  treatment  option  for  this  patient  population.